摘要Esomeprazole, one of the proton pump inhibitors (PPIs), has been widely used in acid-related diseases, such as gastro-esophageal reflux disease and Helicobacter pylori infection. Compared with other PPIs, esomeprazole has higher acid control efficiency, bioavailability, stability, and less interindividual variation depending on its pharmacokinetic properties.Esomeprazole was considered safe for long-term administration. However, several recent studies have contradicted its absolute safety, and some detrimental cases have been reported in some special groups, such as pregnant women and patients with liver cirrhosis. Because acid-related diseases usually require long-term therapy and esomeprazole inhibits CYP2C19 enzyme that increases the probability of drug-drug interaction, these risks have become a concern. Recent studies have shown that esomeprazole not only inhibits acid secretion, but also exhibits acid-independent effects in inflammatory conditions. Esomeprazole can modulate NF-κb activation to resist tissue oxidation and apoptosis in gastric ulcer. In CCL4-induced liver fibrosis, esomeprazole improves oxidative stress, fibrogenesis, and apoptosis, but the mechanism still remains unclear. This review summarized the property of esomeprazole and its potential risk for administration, and its latest research progress, which may facilitate clinicians to better use and avoid the potential risks.
Abstract：Esomeprazole, one of the proton pump inhibitors (PPIs), has been widely used in acid-related diseases, such as gastro-esophageal reflux disease and Helicobacter pylori infection. Compared with other PPIs, esomeprazole has higher acid control efficiency, bioavailability, stability, and less interindividual variation depending on its pharmacokinetic properties.Esomeprazole was considered safe for long-term administration. However, several recent studies have contradicted its absolute safety, and some detrimental cases have been reported in some special groups, such as pregnant women and patients with liver cirrhosis. Because acid-related diseases usually require long-term therapy and esomeprazole inhibits CYP2C19 enzyme that increases the probability of drug-drug interaction, these risks have become a concern. Recent studies have shown that esomeprazole not only inhibits acid secretion, but also exhibits acid-independent effects in inflammatory conditions. Esomeprazole can modulate NF-κb activation to resist tissue oxidation and apoptosis in gastric ulcer. In CCL4-induced liver fibrosis, esomeprazole improves oxidative stress, fibrogenesis, and apoptosis, but the mechanism still remains unclear. This review summarized the property of esomeprazole and its potential risk for administration, and its latest research progress, which may facilitate clinicians to better use and avoid the potential risks.
基金资助:National Natural Science Foundation of China;grant number:81900535
通讯作者:
Fotian Xie, Laboratory of Neuroendocrinology, College of Life Science, Fujian Normal University, Fuzhou 350117, China. E-mail address: lvyi@fjun.edu.cn
引用本文:
Fotian Xie, Yi Lv. Research Progress of Esomeprazole and its Potential Risk for Administration[J]. 中国生物医学工程学报(英文版）, 2020, 29(2): 37-45.
Fotian Xie, Yi Lv. Research Progress of Esomeprazole and its Potential Risk for Administration. Chinese Journal of Biomedical Engineering, 2020, 29(2): 37-45.
[1] Lindberg P,Keeling D,Fryklund J,et al. Review article: Esomeprazole--enhanced bio-availability, specificity for the proton pump and inhibition of acid secretion [J]. Aliment Pharmacol Ther, 2003,17(4):481-488. [2] Andersson T,Hassan-Alin M,Hasselgren G,et al. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole [J]. Clin Pharmacokinet, 2001,40(6):411-426. [3] Vigneri S,Tonini M,Scarpignato C,et al. Improving opportunities for effective management of gastro-oesophageal reflux disease [J]. Dig Liver Dis, 2001,33(8):720-730. [4] Robinson M,Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know [J]. Drugs, 2003,63(24):2739-2754. [5] Eltahir HM,Nazmy MH. Esomeprazole ameliorates CCl4 induced liver fibrosis in rats via modulating oxidative stress, inflammatory, fibrogenic and apoptotic markers [J]. Biomed Pharmacother,2018,97:1356-1365. [6] Yan M,Wu ZF,Tang D,et al. The impact of proton pump inhibitors on the pharmacokinetics of voriconazole in vitro and in vivo [J]. Biomed Pharmacother, 2018,108:60-64. [7] Furuta T,Shirai N,Sugimoto M,et al. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies [J]. Drug Metab Pharmacokinet, 2005,20(3):153-167. [8] Li XQ,Andersson TB,Ahlstrom M,et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities [J]. Drug Metab Dispos, 2004,32(8):821-827. [9] Zvyaga T,Chang SY,Chen C,et al. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19 [J]. Drug Metab Dispos,2012,40(9):1698-1711. [10] Hunfeld NG,Touw DJ,Mathot RA,et al. A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism [J]. Aliment Pharmacol Ther,2010,31(1):150-159. [11] Hunfeld NG,Touw DJ,Mathot RA,et al. A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism [J]. Aliment Pharmacol Ther,2012,35(7):810-818. [12] Litalien C,Theoret Y,Faure C. Pharmacokinetics of proton pump inhibitors in children [J]. Clin Pharmacokinet, 2005,44(5):441-466. [13] Jaspersen D,Labenz J,Willich SN,et al. Long-term clinical course of extra-oesophageal manifestations in patients with gastro-oesophageal reflux disease. A prospective follow-up analysis based on the ProGERD study [J]. Dig Liver Dis, 2006,38(4):233-238. [14] Battaglia E,Grassini M,Navino M,et al. Water load test before and after PPI therapy in patients with gastro-oesophageal reflux disease [J]. Dig Liver Dis, 2007,39(12):1052-1056. [15] Gisbert JP,Pajares JM. Esomeprazole-based therapy in Helicobacter pylori eradication: a meta-analysis [J]. Dig Liver Dis, 2004,36(4):253-259. [16] Frazzoni M,Manno M,De Micheli E,et al. Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole [J]. Dig Liver Dis,2006,38(2):85-90. [17] Tipnis NA,Rhee PL,Mittal RK. Distension during gastroesophageal reflux: effects of acid inhibition and correlation with symptoms [J]. Am J Physiol Gastrointest Liver Physiol,2007,293(2):G469-474. [18] Hong SJ,Park SH,Moon JS,et al. The benefits of combination therapy with esomeprazole and rebamipide in symptom improvement in reflux esophagitis: An international multicenter study [J]. Gut Liver, 2016,10(6):910-916. [19] Dent J,Kahrilas PJ,Hatlebakk J,et al. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease [J]. Am J Gastroenterol, 2008,103(1): 20-26. [20] Attwood SE,Ell C,Galmiche JP,et al. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies [J]. Aliment Pharmacol Ther, 2015,41(11): 1162-1174. [21] Yoon H,Kim N,Kim JY,et al. Effects of multistrain probiotic-containing yogurt on second-line triple therapy for Helicobacter pylori infection [J]. J Gastroenterol Hepatol, 2011,26(1):44-48. [22] Crispino P,Iacopini F,Pica R,et al. Beta-lactamase inhibition with clavulanic acid supplementing standard amoxycillin-based triple therapy does not increase Helicobacter pylori eradication rate [J]. Dig Liver Dis, 2005,37(11):826-831. [23] Johnson DA. Review of esomeprazole in the treatment of acid disorders [J]. Expert Opin Pharmacother, 2003,4(2): 253-264. [24] Cheon JH,Kim N,Lee DH,et al. Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection [J]. Helicobacter, 2006,11(1):46-51. [25] Kang JM,Kim N,Lee DH,et al. Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy [J]. Helicobacter, 2007,12(6):623-628. [26] Song Z,Zhou L,Zhang J,et al. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy [J]. Dig Liver Dis,2016,48(5):506-511. [27] Di Caro S,Franceschi F,Mariani A,et al. Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication [J]. Dig Liver Dis, 2009,41(7):480-485. [28] Zullo A,De Francesco V,Manes G,et al. Second-line and rescue therapies for Helicobacter pylori eradication in clinical practice [J]. J Gastrointestin Liver Dis,2010,19(2):131-134. [29] Zullo A,De Francesco V,Bellesia A,et al. Bismuth-based quadruple therapy following H. pylori eradication failures: a multicenter study in clinical practice [J]. J Gastrointestin Liver Dis,2017,26(3):225-229. [30] De Francesco V,Pontone S,Bellesia A,et al. Quadruple, sequential, and concomitant first-line therapies for H. pylori eradication: a prospective, randomized study [J]. Dig Liver Dis, 2018,50(2):139-141. [31] Kwon YH,Kim N,Lee JY,et al. Comparison of the efficacy of culture-based tailored therapy for Helicobacter pylori eradication with that of the traditional second-line rescue therapy in Korean patients: a prospective single tertiary center study [J]. Scand J Gastroenterol, 2016,51(3):270-276. [32] Lee JW,Kim N,Nam RH,et al. Favorable outcomes of culture-based Helicobacter pylori eradication therapy in a region with high antimicrobial resistance [J]. Helicobacter,2019:e12561. [33] Iacopini F,Crispino P,Paoluzi OA,et al. One-week once-daily triple therapy with esomeprazole, levofloxacin and azithromycin compared to a standard therapy for Helicobacter pylori eradication [J]. Dig Liver Dis,2005,37(8):571-576. [34] Sacco F,Spezzaferro M,Amitrano M,et al.Efficacy of four different moxifloxacin-based triple therapies for first-line H. pylori treatment [J].Dig Liver Dis,2010,42(2):110-114. [35] Gisbert JP,Romano M,Molina-Infante J,et al. Two-week,high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments [J].Dig Liver Dis,2015,47(2):108-113. [36] Yoon H,Kim N,Lee B H,et al. Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate [J]. Helicobacter,2009,14(5):77-85. [37] De Francesco V,Ridola L,Hassan C,et al. Two-week triple therapy with either standard or high-dose esomeprazole for first-line H. pylori eradication [J]. J Gastrointestin Liver Dis,2016,25(2):147-150. [38] Kang JM,Kim N,Lee DH,et al. Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage [J]. J Gastroenterol Hepatol,2008,23(8 Pt 1): 1287-1291. [39] Chen CH,Yang JC,Uang YS,et al. Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel [J]. Biopharm Drug Dispos, 2012,33(5):278-283. [40] Evanchan J,Donnally MR,Binkley P,et al. Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction [J]. Clin Cardiol, 2010,33(3): 168-171. [41] Ogilvie BW,Yerino P,Kazmi F,et al. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel [J]. Drug Metab Dispos,2011,39(11):2020-2033. [42] Nishihara M,Yamasaki H,Czerniak R,et al. In vitro assessment of potential for cyp-inhibition-based drug-drug interaction between vonoprazan and clopidogrel [J]. Eur J Drug Metab Pharmacokinet, 2018. [43] Niece KL,Boyd NK,Akers KS.In vitro study of the variable effects of proton pump inhibitors on voriconazole[J].Antimicrob Agents Chemother,2015,59(9):5548-5554. [44] Becker ML,Franken WP,Karapinar F,et al. Possible drug-drug interaction between high-dose esomeprazole and phenprocoumon [J]. Eur J Clin Pharmacol, 2015,71(12):1461-1465. [45] Thomas B,Mohamed M,Al Hail M,et al. A case of probable esomeprazole-induced transient liver injury in a pregnant woman with hyperemesis [J]. Clin Pharmacol, 2016,8:199-202. [46] Shafik AN,Khattab MA,Osman AH. Magnesium sulfate versus esomeprazole impact on the neonates of preeclamptic rats [J]. Eur J Obstet Gynecol Reprod Biol, 2018,225:236-242. [47] Zaccardi F,Pitocco D,Martini F,et al. A case of esomeprazole-induced transient diabetes and hepatitis: the role of liver inflammation in the pathogenesis of insulin resistance [J]. Acta Diabetol, 2014,51(1):151-153. [48] Tsai CF,Chen MH,Wang YP,et al. Proton pump inhibitors increase risk for hepatic encephalopathy in patients with cirrhosis in a population study [J]. Gastroenterology, 2017,152(1):134-141. [49] Hsin IF,Hsu SJ,Chuang CL,et al. The effects of proton pump inhibitor on hepatic vascular responsiveness and hemodynamics in cirrhotic rats [J]. J Chin Med Assoc, 2018,81(7):585-592. [50] Abrams JA. Chemoprevention of esophageal adenocarcinoma [J]. Therap Adv Gastroenterol, 2008,1(1): 7-18. [51] Gomm W,von Holt K,Thome F,et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis [J]. JAMA Neurol, 2016,73(4):410-416. [52] Novotny M,Klimova B,Valis M. PPI long term use: risk of neurological adverse events[J]. Front Neurol, 2018,9:1142. [53] Park CH,Kim EH,Roh YH,et al. The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis [J]. PLoS One, 2014,9(11):e112558. [54] van der Hoorn MMC,Tett SE,de Vries OJ,et al. The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study [J]. Bone,2015,81:675-682. [55] Sugano K,Kinoshita Y,Miwa H,et al. Safety and efficacy of long-term esomeprazole 20 mg in Japanese patients with a history of peptic ulcer receiving daily non-steroidal anti-inflammatory drugs [J]. BMC Gastroenterol, 2013,13:54. [56] Freedberg DE,Salmasian H,Abrams JA,et al. Orders for intravenous proton pump inhibitors after implementation of an electronic alert [J]. JAMA Intern Med, 2015,175(3):452-454. [57] Colucci R,Fornai M,Antonioli L,et al. Characterization of mechanisms underlying the effects of esomeprazole on the impairment of gastric ulcer healing with addition of NSAID treatment [J]. Dig Liver Dis, 2009,41(6):395-405.
